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Abstract
Background: Intra-articular corticosteroid injections (IACI) are routinely used by pediatric rheumatologists in the
treatment of chronic arthritis. Frequently, topical anesthetics are used to control procedural pain, but their relative
efficacy has not been reported. In this study, we evaluated the level of pain associated with different anesthetic
methods, Numby® 900 Iontophoretic Drug Delivery System, or EMLA® cream, with or without subcutaneous
buffered lidocaine (SQBL), during IACI of the knee in children with arthritis.
Methods: We conducted a prospective study of patients, ages 4 to 21 years old, followed at three pediatric
rheumatology centers who were undergoing IACI of a knee joint. Patients were randomized into two treatment
groups: 1) topical anesthetic only (EMLA® or Numby® (E/N)), or 2) topical anesthetic (E/N) and SQBL. Pain was
assessed at baseline, during topical anesthetic placement, and following the IACI (post-procedure). The Faces Pain
Scale-Revised (FPS-R), the Face, Leg, Activity, Cry, Consolability (FLACC) behavioral scale and the parental global
assessment (PGA) (0 = best experience, 10 = worst experience) were determined.
Results: Sixty-three patients (44 females) with a median [IQR] age of 10.8 [IQR = (8.2–14.4)] years (range 4.7–20 years)
with active knee arthritis were consented. FPS-R post-procedure (P = 0.03), FLACC (P = 0.02) and PGA (P = 0.01) scores
were significantly lower in females treated with E/N plus SQBL compared to patients treated with E/N only. Females in
the E/N only group had a significant worsening of their baseline pain (p < 0.0004) and a greater magnitude of change
in their baseline FPS-R scores (p < 0.001) from the procedure compared to females in the E/N plus SQBL group who
had no worsening of their baseline pain. No significant change in pain level or PGA score was found among males in
either treatment group. Pain scores overall were similar to the oligoarthritis patients, a more homogeneous group of
patients. Both EMLA® (n = 33) and Numby® (n = 29) were equally well tolerated with no significant difference in median
FPS-R administration scores overall.
Conclusion: Our results suggest that a topical anesthetic plus SQBL is more effective for injection pain control than
topical anesthesia only. Further studies addressing pain and anxiety will help determine the optimal method of pain
control for IACI.
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Background
Intra-articular corticosteroid injections (IACI) are one
of the mainstays of treatment for patients with chronic
arthritis and are part of the 2011 American College of
Rheumatology recommendations for the treatment of
juvenile idiopathic arthritis (JIA) [1–4]. IACI enables
the physician to deliver localized treatment and may re-
duce the need for, or serve as an adjunct to, systemic
medications. IACI may be used in patients with reactive
arthritis, JIA, Lyme arthritis, and arthritis secondary to
an underlying autoimmune disease such as systemic
lupus erythematosus. Survey data show that 90 % of
pediatric rheumatologists would recommend IACI as
either initial therapy or after unsuccessful therapy with
non-steroidal anti-inflammatory drugs. Furthermore
both parents preference and a decision analysis identi-
fied IACI as the preferred initial management of knee
monoarthritis in JIA [2, 4].
Despite the frequent use of IACI, little attention has
been paid to the pain and distress that may be associated
with the procedure, and there is no established standard
regarding the type of anesthesia to use for IACI. Both bio-
logical (i.e.,: age, sex) and psychological factors contribute
to the fear and perception of pain and pain scores [5].
Minimizing the pain, anxiety and stress associated with
the procedure is important to improve patient cooperation
and to avoid unsuccessful procedural attempts [6]. Chil-
dren experience pain, stress, and anxiety when undergoing
IACI and it is important to treat the procedural pain both
to limit suffering and to prevent lasting changes in pain
systems and pain responses that may result in anticipatory
anxiety and a heightened pain response with future proce-
dures [6]. Being able to minimize pain and calm the pa-
tient will make the procedure more satisfying for all
involved while ideally reducing the time it takes to per-
form the procedure.
Local anesthesia for IACI may include topical prepa-
rations such as EMLA® cream (AstraZeneca, Inc) or
LMX-4 (Ferndale Laboratories) [1, 3], lidocaine ionto-
phoresis, ethyl chloride spray (Gebauer Co.) and sub-
cutaneously administered lidocaine [3]. Numby® 900
Iontophoretic Drug Delivery System (Iomed, Inc., Salt
Lake City, UT) delivers a lidocaine HCL 2 % and epi-
nephrine 1:100,000 topical solution into the skin under
the influence of electric current. Lidocaine iontophor-
esis has a greater depth of penetration (8.6 mm after a
20 min application) [7] over a shorter period of time
than EMLA® (5 mm after a 60 min application) [8]. Al-
though one study found EMLA® to be ineffective for re-
ducing the pain of IACI in children with juvenile
rheumatoid arthritis, it is routinely used in clinical
practice [1].
To determine the methods of local and general anesthesia
currently being used by pediatric rheumatologists, a survey
was conducted in 2006 of all members of the Childhood
Arthritis & Rheumatology Research Alliance (CARRA),
a major research collaborative organization of pediatric
rheumatologists in North America [3]. Fifty-nine per-
cent of respondents reported using EMLA®, while lido-
caine iontophoresis was used by 11.8 % of respondents
[3]. Sixty-six percent of physicians believe that giving
subcutaneous lidocaine actually contributes to proced-
ural pain. Sub-cutaneous buffered lidocaine was rarely
used. Conscious sedation (CS) or general anesthesia
(GA) was used by 85 % of physicians, usually at the dis-
cretion of the anesthesiologist [3]. The agents most fre-
quently used were midazolam intra-venously (39.5 %),
gas (i.e.,: nitrous oxide) (30 %) and propofol (19 %) or
fentanyl or vistanyl (19 %) [3]. Interestingly, only 30 %
of physicians use gas for IACI even though studies have
shown it to be safe and effective for JIA patients under-
going IACI [9, 10]. Ideally, successful use of a local
anesthetic would reduce the number of patients treated
with CS or GA minimizing risks such as respiratory
depression.
The anesthetic effect of EMLA® versus lidocaine
iontophoresis for IACI has not been studied, nor is it
known whether the addition of subcutaneous buffered
lidocaine (SQBL) is beneficial. Our objective in this
open-label prospective, randomized trial was to deter-
mine the optimal method of delivering local anesthesia
for IACI by comparing two treatment groups: Numby®
900 Iontophoretic Drug Delivery System or EMLA®
cream with or without subcutaneous buffered lidocaine
(E/N + SQBL) or E/N only.
Method
Patients
Patients between 4 and 21 years of age with JIA or Lyme
arthritis with chronic, active arthritis of at least one knee
and who were prescribed an IACI were eligible for par-
ticipation in the study and enrolled between April 2006
and November 2008. Exclusion criteria included: 1) al-
lergy to lidocaine or any ingredient used in Numby® or
EMLA®, 2) use of an electrically sensitive support system
(i.e., pacemakers), 3) damaged skin or signs of infection
at the proposed injection site, 4) coagulopathy, or 5) in-
ability to evaluate pain associated with the procedure.
This study was approved by the Institutional Review
Boards of Hackensack University Medical Center,
Hackensack, NJ, St. Barnabas Medical Center, Livingston,
NJ and Connecticut Children’s Medical Center, Hartford,
CT. Written informed consent from parents and written
informed assent when child >9 years old were obtained.
Measures
The Faces Pain Scale-Revised (FPS-R) is a self-report
measure consisting of 6 gender-neutral faces depicting
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increasing intensity of pain that corresponds to a 0–10
metric pain scale (0 = no pain,10 = worst pain). Studies
have demonstrated that the FPS-R correlates highly with
other self-report pain scales and children ≥4 years of age
are able to use the scale [11]. Although often used for
younger or non-verbal patients, a Face, Leg, Activity,
Cry, and Consolability (FLACC) score was obtained in
all patients, regardless of age. [12]. It is an observational
pain scale that is used for young or sedated children and
supplements self-report pain scales such as the FPS-R
[12]. The FLACC score rates the above 5 parameters on
a scale of 0–2 points for a maximum score of 10 (worst
pain) [12]. A parental global assessment (PGA) was re-
corded based on the parent’s perceptions of the patient’s
overall procedure experience at the completion of the
procedure (0 = best experience, 10 = worst experience).
All three of these measures were endorsed as outcome
measures for acute pain trials by the Pediatric
IMMPACT group [13].
Procedure
Patients were randomized into one of four groups.
Group 1 had 2.5 g of EMLA® applied with occlusive
dressing (Tegaderm®; 3 M, St. Paul, MN) for 60 min.
Group 2 had 2.5 ml of the lidocaine hydrochloride 2 %
and epinephrine 1:100,000 topical solution placed on the
Numby® 900 electrode pad and then placed on the pa-
tient at the injection site for 20 min. The dispersive pad
was placed over a major muscle group 10–15 cm away
from the drug electrode. Numby® 900 was started at
2.0 mA for 20 min. Group 3 had EMLA® applied as
above plus an injection of SQBL (9:1 2 % lidocaine to so-
dium bicarbonate). Group 4 had Numby® 900 applied as
above plus an injection of SQBL.
A FPS-R score was obtained from the patient at 3 time
points: 1) upon arrival to the office (FPS-R baseline),
2) once the topical anesthetic was removed, before
the needle was inserted (FPS-R topical anesthetic) to reflect
discomfort from the anesthetic and 3) at completion of the
procedure (FPS-R post-procedure) to reflect procedure
pain. A FLACC score and PGA were recorded.
IACI procedure
Parents were present during the procedure. A child life
specialist or experienced nurse was present to provide
psychosocial support, distraction and to improve pa-
tients’ and parents’ understanding of the procedure.
After the skin was sterilized with povidone-iodine and
alcohol, a 21 gauge needle on a 3 ml syringe was
inserted into the joint space through a medial approach.
In the SQBL group, the syringe was filled with buffered
lidocaine and the periarticular space was slowly infil-
trated at physician discretion. The needle was then ad-
vanced into the joint space, syringe was then replaced
with a sterile empty syringe and the synovial fluid was
aspirated. With the needle remaining in place, the con-
tents of a syringe containing 1 mg/kg (maximum
100 mg) of triamcinolone hexacetonide was injected.
Statistical analysis
Continuous random variables were summarized as mean
(standard deviation) or median (inter-quartile range) de-
pending on whether or not the data followed the normal
distribution. Categorical responses were presented as
frequencies (percentages). With a two-tailed test with
significance level of 5 % and a defined clinically signifi-
cant difference of 1.5 standard deviations on the primary
outcome, pain, and power of 80 %, we calculated that a
sample size of 72 patients (18/group) was required. Be-
cause this target was not achieved, we aggregated the
four treatment groups into two treatment groups a) pa-
tients who received EMLA® or Numby® only (E/N) and
b) patients who received EMLA® or Numby® plus SQBL
(E/N + SQBL). Continuous variables, age, disease dur-
ation, pain scores and global assessment were not nor-
mally distributed as indicated by the Shapiro-Wilk test.
Hence, comparisons between any two groups were con-
ducted using a Wilcoxon rank sum test. Comparisons of
two groups with respect to categorical variables, gender,
disease type, were performed using Chi-square test or
Fisher Exact test as appropriate.
Subgroup analysis of pain scores was conducted in
the cohort of oligoarthritis patients, the most com-
mon JIA subtype and a more homogeneous group of
patients. Females reportedly have higher pain scores
[5], so comparative analyses examined if sex effects
were significant. Wilcoxon signed-rank test was used
to compare the changes in FPS-R (post-procedure) -
FPS-R (baseline). Further, the paired differences were
compared across pain management methods using
Wilcoxon rank sum test taking into account patients’
pain score at baseline. All statistical analyses were
performed using SAS software version 9.2 (SAS Institute
Inc., Cary, NC).
Results
Seventy-seven patients were approached for the study
and 63 (44 girls) (Table 1) agreed to participate. Rea-
sons for refusal were preference for topical anesthesia
(13 patients) or refusal to have a child-life therapist
present (1 patient). The median age of study patients
was 10.8[IQR = (8.2 to 14.4)] years (range 4.7–20 years),
and over 80 % were Caucasian. There was no significant
difference between treatment groups for disease dur-
ation or any demographic parameter (Table 1).
In the E/N only group (n = 28), the median FPS-R
baseline score was 0.0 [IQR = (0.0 to 2.0)] and the median
FPS-R post-procedure score was higher at 3.0 [IQR = (2.0
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to 6.0)]. In the E/N plus SQBL group (n = 35), both the
median FPS-R baseline score and FPS-R post-procedure
score were 2.0 [IQR = (0.0 to 4.0)] and 2.0 [IQR = (1.0 to
4.0)], respectively. A comparison between patients in the
two treatment groups using the FPS-R post-procedure
and FLACC scores did not reveal any significant dif-
ferences. There was a significant difference in the
PGA (P = 0.005).
Looking at all patients, there was no significant differ-
ence between treatment groups with regards to mild,
moderate and severe pain. When examining the groups
based on gender, the female patients in the E/N only
group had significantly worse procedure pain (P = 0.03)
with 21 % of patients having severe pain (FPS-R score
7.0–10.0) (Table 2) [14]. There was no significant differ-
ence between males.
Because it was determined that there was a significant
interaction between gender and FPS-R (P = 0.02),
FLACC (P = 0.04) and PGA (P = 0.005) scores, subse-
quent comparisons between treatment groups were
performed within each gender (Table 2). Females in the
E/N plus SQBL group had significantly lower FPS-R,
FLACC and PGA post procedure scores. Overall, males
(n = 19) in the two treatment groups did not have a sig-
nificant difference in median pain or PGA scores. These
findings held true even when the more homogenous
group of oligoarticular JIA patients were compared
(Table 3).
Nineteen patients (31 %) (13 F) had a prior IACI.
The Friedman rank test revealed a significant inter-
action between gender and prior IACI with the FPS-R
(P > 0.03), therefore, comparisons were performed
within each gender. With the exception of the FLACC
scores in males, those patients who had a prior IACI
did not experience worse pain compared to patients
who never had a prior IACI, independent of their gen-
der (P > 0.05).
Table 4 compares the change in FPS-R scores from
baseline to post-procedure between treatment groups
within each gender. Females in the E/N group had a sig-
nificant worsening (p = 0.0004) of their baseline pain
(pain related to their active arthritis) by 2 points com-
pared to the females in the E/N plus SQBL group that
had no worsening of their baseline pain from the pro-
cedure (Table 4, Fig. 1). Within each topical anesthetic
treatment group the change in FPS-R scores from base-
line to post-procedure were examined, and females in
the E/N only group had worsening of their baseline pain
from the procedure (p = 0.001) (results not shown). No
significant change in pain level was found among males
either between or within treatment groups.
Both EMLA® (n = 33) and Numby® (n = 29) were
equally well tolerated with no significant difference in
median FPS-R administration scores overall. Adverse
events were minor. In the Numby® 900 group, they
included: blanching (n = 17), redness (n = 13), and
complaints of “tingling” (n = 14), “itching” (n = 7),
“pain” (n = 6), and “burning” (n = 4). In the EMLA®
group, they included blanching (n = 21), redness (n = 9),
and complaints of “itching” (n = 1).
Table 1 Characteristics of arthritis patients receiving intra-articular
corticosteroid injections
Characteristics All EMLA® or
Numby®b
EMLA® or Numby® +
Buffered Subcutaneous
Lidocaineb
Total n (%) 63 (100) 28 (44.4) 35 (55.6)
Agea (years) 10.8 (8.2– 14.4) 11.5 (8.7 – 13.1) 10.5 (8.2 – 14.6)
Range (years) 4.7 – 20 4.7 – 17.9 6.1 – 20.0
Gender
Male 19 (30.2) 9 (32.1) 10 (28.6)
Female 44 (69.8) 19 (67.9) 25 (71.4)
Disease Durationa
(years)
1.2 (0.2 – 4.8) 1.4 (0.11 – 4.7) 1.2 (0.2 –5.0)
Range (years) 0 – 15.6 0.0 – 9.6 0.02 – 15.6
Disease Type
Oligoarthritis 49 (77.8) 24 (85.7) 25 (71.4)
Polyarthritis 7 (11.1) 2 (7.1) 5 (14.2)
Systemic arthritis 1 (1.6) 0 (0.0) 1 (2.9)
Enthesitis-Related
arthritis
1 (1.6) 1 (3.6) 0 (0.0)
Psoriatic arthritis 2 (3.2) 1 (3.6) 1 (2.9)
Lyme arthritis 3 (4.8) 0 (0.0) 3 (8.6)
aMedian [inter-quartile range (IQR) = 25th- 75th percentile]. bNo significant
difference between groups
Table 2 Pain severity of intra-articular corticosteroid injections
between treatment groups using Faces Pain Scale-Revised
post-procedure scores
Patients Pain severity EMLA® or
Numby®
(n = 28)




All (n = 63) Mild 14 (50.0) 23 (65.7)
Moderate 10 (35.7) 11 (31.4) 0.2367
Severe 4 (14.3) 1 (2.7)
Male (n = 19)
Mild 7 (77.8) 7 (70.0)
Moderate 2 (22.2) 2 (20.0) 1.000
Severe 0 (0.0) 1 (10.0)
Female (n = 44)
Mild 7 (36.8) 16 (64.0)
Moderate 8 (42.1) 9 (36.0) 0.0260*
Severe 4 (21.1) 0 (0.0)
All data entries are counts (percentages). Pain scores: Mild: (0–3.9); Moderate
(4.0 –6.9); Severe (7.0 –10.0). *P < 0.05 was considered statistically significant
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Discussion
The results of our study suggest that a combination of
E/N plus SQBL along with supportive staff to aid in
relaxation techniques offers improvement in pain con-
trol compared to E/N alone for the IACI procedure.
Over 40 % of clinicians feel that parent and patient
anxiety were issues regarding the type of anesthesia to
be used for IACI, and even if the IACI should be pre-
scribed at all [2, 3]. Clinician’s also viewed insufficient
nursing or medical support and insufficient means for
patient sedation as obstacles to IACI [2]. Our study
results will reassure clinicians, patients, and their fam-
ilies that pain from IACI is mild in most cases and
may encourage clinicians to do more injections in the
office with only local anesthesia, and not use con-
scious sedation, if support staff such as a child life
therapist or a skilled nurse is available for support of
the patient and parents.
Patients in the E/N plus SQBL group had higher base-
line pain scores, however, there was no statistically sig-
nificant difference between the two groups. Those
patients with the higher baseline pain scores may have a
lower threshold for pain or greater anxiety about the up-
coming procedure.
Those patients not treated with SQBL during the IACI
procedure had worsening of their baseline arthritis pain
in contrast to the group that received the SQBL who
had no worsening of their baseline pain (Table 4). Fe-
males who only received E/N tended to have higher me-
dian FPS-R post procedure scores and more severe
procedure pain. These results are especially important
since JIA overall has a female predominance, especially
within the oligoarthritis sub-type.
More important than statistical significance is a
minimal clinically important difference (MCID) in
pain scores, in which the patient would find the pro-
cedure pain tolerable. Prior studies have shown a 2
point change in score out of 10 points (or 1 face) on
the FPS to be clinically significant [15]. Our study has
demonstrated a MCID in pain scores. Those patients
that only received E/N had a worsening of their base-
line pain as demonstrated by an increase in their score
of 2 points (1 face) compared to the group that re-
ceived SQBL who had no worsening of their pain from
the procedure. Tsze, et al. defined mild pain as a score
of 0–3.9, moderate pain as a score of 4–6.9 and severe
pain as a score of 7–10 [14]. If we apply this definition
to our cohort, the patients in the E/N plus SQBL
Table 3 Pain scores post-procedure in childhood arthritis by treatment group
Male (n = 19) Female (n = 44)
EMLA® or
Numby® (n = 9)
EMLA® or Numby® + Subcutaneous
Buffered Lidocaine (n= 10)
P-value EMLA® or
Numby® (n = 19)
EMLA® or Numby® + Subcutaneous
Buffered Lidocaine (n= 25)
P-value
All patients (63)
FPS-R (63) 2.0 (2.0–2.0) 1.5 (0.0–4.0) 0.64 5.0 (2.0–6.0) 2.0 (2.0–4.0) 0.03*
FLACC (56) 0.0 (0.0–1.0) 1.0 (0.0–2.0) 0.53 2.5 (0.0–6.0) 0.0 (0.0–3.0) 0.02*
PGA (61) 2.0 (1.0–2.0) 0.5 (0.0–2.0) 0.37 2.0 (1.0–5.0) 0.0 (0.0–2.0) 0.01*
Oligoarthritis patients (49)
FPS-R (49) 2.0 (2.0–4.0) 1.0 (0.0–2.0) 0.25 6.0 (2.0–6.0) 2.0 (2.0–4.0) 0.06
FLACC (42) 1.0 (0.0–1.0) 1.0 (0.0–4.0) 0.74 3.5 (0.5–7.0) 0.0 (0.0–2.0) 0.01*
PGA (48) 2.0 (1.0–2.0) 1.5 (0.0–2.0) 0.54 2.0 (1.0–3.0) 0.0 (0.0–1.0) 0.01*
Pain scores are reported as Median (IQR: 25th-75th percentiles); IQR = inter quartile range, FPS-R = Faces Pain Scale-Revised, FLACC = Faces, Leg, Affect, Cry,
Consolability scale, PGA = parental global assessment. Two- sided Wilcoxon Rank Sum Test was used to compare pain scores between groups. *P < 0.05 was
considered statistically significant
Table 4 Comparison of Faces Pain Scale-Revised (FPS-R) scores from IACI in childhood arthritis between treatment groups by gender
Male (n = 19) Female (n = 44)
EMLA® or Numby®
Only (n= 9)
EMLA® or Numby® + Subcutaneous
Buffered Lidocaine (n= 10)
EMLA® or Numby®
Only (n = 19)
EMLA® or Numby® + Subcutaneous
Buffered Lidocaine (n= 25)
Change in FPS-R
score
Change in FPS-R score P-value Change in FPS-R
score
Change in FPS-R score P-value
All patients (n = 63) 1.0 (0.0–2.0) 0.5 (0.0–2.0) 0.61 2.0 (2.0–5.0) 0.0 (0.0–2.0) 0.0004*
Oligo-arthritis (n= 49) 2.0 (0.0–4.0) 0.0 (0.0–2.0) 0.16 2.0 (2.0–5.0) 0.0 (−1.0–1.0) 0.0006*
Pain scores are reported as Median (IQR: 25th-75th percentiles); Change in FPS-R scores = FPS-R post-procedure – FPS-R baseline; Comparison of the changes in
FPS-R scores between treatment groups were examined using Wilcoxon rank sum test. IACI = intra-articular corticosteroid injection. *P < 0.05 was considered
statistically significant
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group had minimal procedure pain, whereas, the FPS-
R scores were moderate (5–6) in the E/N only group.
Topical anesthetic plus SQBL resulted in excellent in-
jection pain control as evidenced by low pain scores
and a MCID in pain scores.
A contributing factor to our low pain scores may be
our use of a child life therapist during the procedure.
Child life therapists play an important role in helping
patients cope with anxiety and procedure pain by
reassuring and distracting them and by employing
relaxation techniques. Studies have shown that develop-
mentally appropriate behavioral and cognitive pain man-
agement strategies (i.e.,: deep breathing, reassurance) are
often effective in pain control [16, 17]. Weintraub, et al.
Fig. 1 a Comparison of Faces Pain Scale-Revised (FPS-R) pre- and post-procedure scores in male patients (n = 19) during intra-articular corticosteroid
injection. b Comparison of Faces Pain Scale-Revised (FPS-R) pre- and post-procedure scores in female patients (n = 44) during intra-articular
corticosteroid injection
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found that children with JIA undergoing IACI using self-
administered nitrous oxide with a medical clown in attend-
ance prior to and during the procedure had low visual
analog scores of 1 [11].
Buffering the lidocaine, which is acidic (pH 3.5–7),
with sodium bicarbonate and administering slowly is
also an important step in reducing procedural pain as it
reduces the burning sensation associated with its infil-
tration into skin (pH 7.35–7.45) [18]. A Cochrane re-
view published in 2010 reported that both adult and
pediatric patients preferred buffered lidocaine in both
parallel and cross-over trials and no adverse events
were reported [18].
Both topical anesthetics were well tolerated with no
significant difference in FPS-R administration scores.
Blanching was the most common side effect of both
agents which is to be expected due to their vasocon-
strictive properties. Our patients tolerated the electric
current from the lidocaine iontophoresis which was an
important finding since this modality has a faster on-
set of action and a greater depth of penetration than
EMLA® cream. A study looking at determinants of
success and failure of EMLA® found that while EMLA®
has proven to be safe, it seems to offer less pain con-
trol, at least when applied for 60 min, compared to
iontophoresis [19]. It is recommended that EMLA® be
applied for a minimum of 90 min, preferably 120 min
for intravenous cannulation [19]. Based on these
findings, and reports by others regarding ease of use
and tolerability, lidocaine iontophoresis may be the
topical anesthetic of choice to use in a busy clinic
setting [3, 6].
There were several limitations of our study including
small sample size, open-label, and age of our study popula-
tion. The number of patients needed to adequately power
this study was not achieved. The median patient age in our
study was 10.8 [IQR = (8.2 to 14.4)] years, so expanding the
study to include a greater number of younger children
would be useful to determine if our findings are applicable
to children less than 5 years of age. This study was not
blinded and therefore the patient may have a biased re-
sponse to their treatment based on the physician’s or
nurse’s attitudes about the anesthetic used. Normal syno-
vium may be up to 45 mm thick, but inflamed synovium
can be significantly thickened [20]. This can contribute to a
more painful procedure, and ultrasound was not used to
measure synovial thickness or as an injection guide.
Conclusion
IACI are routinely used by pediatric rheumatologists
and since patients frequently need repeat injections, it is
important to identify strategies that minimize pain to
better ensure patient cooperation and compliance with
the current and future procedures. Our results suggest
that the addition of subcutaneous buffered lidocaine to a
topical anesthetic is an improvement over topical agents
alone, especially in females. Future studies addressing
pain and anxiety around IACI are needed to establish
the best practices for performing IACI.
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